

## **REMARKS**

### ***Amendments to the Specification***

The specification has been amended to correct formalities, typographical errors or clerical errors as follows:

a) Paragraph at page 1 starting at line 11 and ending at line 1 was amended to add continuity information with respect to co-pending application 09/276,595 and information pertaining to the requirements for a statement of federally sponsored research or development;

b) and c) Paragraphs

on page 6, starting at line 32 and ending at line 33 and

on page 6, starting at line 35 and ending at line 36

were amended to add SEQ ID: 1;

d) Paragraph at page 20 starting at line 17 and ending at line 20 was amended to include the patent number information related to applications 08/213,053 and 08/430,355;

e) Paragraph starting on page 31 line 16 and ending on page 32 line 34 was amended to correct the glycoconjugate structure, and to move the definition of R<sub>4</sub>;

f), g) and h) Paragraphs:

(i) on page 11 starting at line 11 and ending at line 22;

(ii) on page 19 starting at line 1 and ending at line 13;

(iii) on page 26 starting at line 12 and ending at line 24;

(iv) on page 17 starting at line 1 and ending at line 21; and

(v) on page 21 line 17 and ending on page 22;

were amended to distinguish the terminal substituents R<sub>0</sub> and R'<sub>0</sub> on each of the recited carbohydrate moieties, which substituents may be the same or different;

i) through p) Paragraphs (structures):

(i) on page 22, lines 20-25;

(ii) on page 28, the first structure starting at line 5

(iii) on page 23, lines 1-9;

(iv) on page 27, starting at line 20 to the end of the page;

- (v) on page 23, line 11 to line 25;
- (vi) on page 28, the second structure;
- (vii) on page 24, lines 1-4;
- (viii) on page 29, first structure;
- (ix) on page 29, second structure;
- (x) on page 24, second structure;
- (xi) on page 24, third structure;
- (xii) on page 29, third structure;
- (xiii) on page 24, fourth structure;
- (xiv) on page 29, fourth structure;
- (xv) on page 25, first structure; and
- (xvi) on page 30, first structure;


were amended to correct the chemical structures, more specifically the points of attachment (for example, since the O atom is already present in the backbone structure (e.g., as OR<sub>A</sub>), the carbohydrate moiety was amended to remove the oxygen atom); and

- q) The abstract was amended to correct typographical errors.

Applicant respectfully submits that no new matter is added with these amendments.

#### *Addition of Claims*


Applicant has canceled all the originally filed claims and has presented new claims 59-100, drawn to constructs having the structure:




pharmaceutical compositions containing them and methods of using them.

Applicant submits that newly added claims 59-100 are fully supported by the specification and that no new matter is added with these additions. Specifically, claim 59 finds support throughout the specification (for example on pages 10 and 11) and Figures 25-29, and *inter alia* in original claim 1. Claims 60-62, 65-69 and 72-83 find support throughout the specification (for example, pp. 10-11 and 20-25) and Figures 25-29. Support for claims 63 and 64 can be found, for example, in Figures 25, 28 and 29. Support for claim 70 can be found throughout the Figures, for example, in Figures 25 and 28A. With respect to the language referring to  $\alpha$ -linkage to the peptide backbone in claim 71, support can be found throughout the specification and figures, where  $\alpha$ -linked glycopeptides are described. With respect to the language referring to  $\beta$ -linkage to the peptide backbone in claim 71, support can be found, for example, in Figure 29, where a compound comprising carbohydrate domains  $\beta$ -O-linked to the peptide backbone is described.

Claims 72 and 81 recite a carbohydrate having the structure:



; support for which can be found, for example, on page 20 lines 9-12 of the specification, in the recitation of "MBr1 epitope" (*i.e.*, Globo-H hexasaccharide), truncated pentasaccharide and tetrasaccharide thereof. Claims 72 and 83 recite a carbohydrate having the structure:



; support for which can be found, for example, in Figure 9 in the teaching that the  $\text{Le}^y$  carbohydrate domain may be a pentasaccharide or hexasaccharide. Claims 84 and 85 find support, for example, in Figure 28B, where a trimeric  $\text{Le}^y$  hexasaccharide glycoconjugate is described. Support for claims 86 and 87 can be found, for example, in Figure 29 where trimeric  $\text{Le}^y$  pentasaccharide glycoconjugates are described.

Claims 88-89 and 90-100 are pharmaceutical composition claims and method of use claims, respectively, corresponding in scope to the compound of claim 1.

Applicant respectfully requests consideration of these newly added claims and submits that they do not present new matter.

#### *Amendments to the Drawings*


Figures 9 and 27 have been amended to correct typographical errors or clerical errors, as detailed in the enclosed letter entitled “*Amendment to Formal Drawing*”.

#### Conclusion

Applicant respectfully submits that no new matter is added with these amendments. Applicant thanks the Examiner in advance for favorable review of this preliminary amendment. If it is believed that a telephone conversation would expedite matters, the Examiner is invited to contact the undersigned at (617) 248-5150.

The Commissioner is hereby authorized to charge any additional fee(s) incurred by the filing of the present Amendment or credit any overpayment to Deposit Account No. 03-1721.

Respectfully submitted,



---

Nadège M. Lagneau, Ph.D.  
Registration No. 51,908

Dated: June 19, 2003

PATENT GROUP  
CHOATE, HALL & STEWART  
Exchange Place  
53 State Street  
Boston, MA 02109  
(617) 248-5150

Page 31 of 31

Express Mail No.: EV 124826102 US  
3573497v2

Attorney Docket No.: 2003080-0127  
Client Reference No.: SK-816-CON

### **AMENDMENTS TO THE DRAWINGS**

Applicant has detailed proposed amendments to Figures 9 and 27 in a separate letter, which is provided herewith (*Amendment to the Drawing*; MPEP 608.02 (r)), along with a marked-up copy of the Drawings to show changes made and a copy of proposed replacement Drawings.